Pfizer Inc.’s stock rose handily Tuesday after the drug manufacturer said it’s trending toward the higher end of its 2025 ...

Australian study finds no adverse impact of repeated Covid vaccinations on metabolism, inflammation, or cardiovascular ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

The company disclosed revenue of $13.7 billion and adjusted earnings of $0.92 per share, compared to consensus estimates of ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research ...

Pfizer said today it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research operations and reported lower first-quarter revenue due to declining sales of its ...

A new Danish study delivers eye-opening results about the COVID-19 vaccines against new virus variants. The post New Danish ...

Pfizer said it still expects adjusted 2025 profit of $2.80 a share to $3 a share, while analysts expect full-year earnings of $2.94 a share. Pfizer also projected 2025 revenue of $61 billion to $64 ...

Novavax said Monday that the Food and Drug Administration was asking the company to run a new clinical trial of its vaccine.

Pfizer recorded lower first-quarter revenue on a 75% drop in sales of its Covid-19 treatment, which more than offset growth in other drugs and product categories. The drugmaker posted a profit of ...